Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07172607

The Effect of Avnace eZZe on Sleep Improvement

This study aims to examine the effectiveness of Avance eZZe drink with liposomal technology in improving sleep quality. Participants will be randomly assigned to either the placebo group, Avance eZZe drink group, and Avance eZZe drink without liposomal group, with 25 participants in each group. On the day of the experiment (day 0), participants are required to fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions. Subsequently, participants will be given the experimental samples and instructed to consume them 1 hour before sleep daily for 28 days. Follow-up assessments will be conducted in the day-1, day-14 and day-28, participants are required to fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Taipei Medical University

Taipei, 110, Taiwan

Location status: Recruiting

Location contact

Hsin-Chien Lee, Doctor

CONTACT

[email protected]

+886-02-22490088 ext. 79213/8158

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female age 18 years or older;
  • Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5) criteria for Insomnia Disorder;
  • Regular bedtime, between 21:00 and 01:00 and regular wake time;
  • Insomnia Severity Index (ISI) score ≥15;
  • All medications or interventions for insomnia, mental or physical disorders must have been stable for at least four weeks prior to screening, and participants had to be willing to maintain a stable regimen throughout the study;
  • No consumption of sleep or stress-related supplements for at least four weeks prior to screening;
  • Willing and able to comply with all aspects of the protocol.

Exclusion criteria

  • A current diagnosis of sleep-related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm sleep disorder;
  • Depressive symptoms at screening were considered significantly severe with a PHQ-9 score > 14
  • Anxiety symptoms at screening were considered significantly severe with a GAD-7 score > 15;
  • Females who are breastfeeding or pregnant;
  • Females of childbearing potential who are not practicing acceptable pregnancy prevention methods (NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal or have been sterilized surgically.);
  • Excessive caffeine use that in the opinion of the investigator contributes to the participant's insomnia, or habitually consumes caffeine-containing beverages after 18:00 and is unwilling to forego caffeine after 18:00 for the duration of his/her participation in the study;
  • History of drug or alcohol dependency or abuse within approximately the previous 2 years;
  • Current evidence of clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal, neurological, or psychiatric disease or malignancy or chronic pain that in the opinion of the investigator could affect the participant's safety or interfere with the study assessments;
  • Scheduled for major surgery during the study;
  • Participants known to be allergic to any components of the product.

Treatment and study plan

Avance eZZe drink

Dietary Supplement

25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily

Avance eZZe drink (without liposomal)

Dietary Supplement

25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily

Placebo drink

Dietary Supplement

25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily

Primary outcomes

  1. Sleep monitoring

    Time frame: Day-0 (baseline), Day-1, Day-14, Day-28

    The difference of electrocardiosignal between two specific points on the body surface will be used to reflect sleep state.

  2. Sleeping quality

    Time frame: Day-0 (baseline), Day-14, Day-28

    The Pittsburgh Sleep Quality Index (PSQI) will be utilized to assess sleeping quality. The minimum value is 0, the maximum value is 42. The higher the score, the worse the outcome.

  3. Insomnia Severity

    Time frame: Day-0 (baseline), Day-14, Day-28

    The Insomnia Severity Index (ISI) will be utilized to assess insomnia severity. The total score ranges from 0 to 28, with higher scores indicating more severe insomnia.

Secondary outcomes

  1. General level of daytime sleepiness

    Time frame: Day-0 (baseline), Day-14, Day-28

    The Epworth Sleepiness Scale (ESS) will be utilized to assess the general level of daytime sleepiness. The total score ranges from 0 to 24, with higher scores indicating greater daytime sleepiness.

  2. Depression severity

    Time frame: Day-0 (baseline), Day-14, Day-28

    Patient Health Questionnaire-9 (PHQ-9) will be utilized to assess depression level. The total score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms.

  3. Anxiety severity

    Time frame: Day-0 (baseline), Day-14, Day-28

    Generalized Anxiety Disorder-7 (GAD-7) will be utilized to assess anxiety level. The total score ranges from 0 to 21, with higher scores indicating greater anxiety severity.

  4. Low Frequency/High Frequence (LF/HF) ratio

    Time frame: Day-0 (Baseline), Day-1, Day-14, Day-28

    A sleep monitoring system will be utilized to measure LF/HF ratio.

Study contacts

Contact information is provided by the study sponsor or research team.

Hsin-Chien Lee, Doctor

CONTACT

[email protected]

+886-02-22490088 ext. 79213/815

Ping Lin

CONTACT

[email protected]

+886-02-87977811

Sponsors and collaborators

Lead sponsor

TCI Co., Ltd.

Industry

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 15, 2025
Registry last updated
Feb 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.